˜_•¶
‘n–ò‰»ŠwE¶•¨—L‹@‰»Šw
Šj“àŽó—e‘̃ŠƒKƒ“ƒh
Toshihiko Tashima, Hiroyuki Kagechika, Motonori Tsuji, Hiroshi Fukasawa, Emiko Kawachi, Yuichi Hashimoto, Koichi Shudo. Polyenylidene Thiazolidine Derivatives with Retinoidal Activities. Chem. Pharm. Bull.,1997, 45, 1805-1813.
Kiminori Ohta, Motonori Tsuji, Emiko Kawachi, Hiroshi Fukasawa, Yuichi Hashimoto, Koichi Shudo, Hiroyuki Kagechika. Potent Retinoid Synergists with a Diphenylamine Skeleton. Biol. Pharm. Bull.,1998, 21, 544-546.
Toru Iijima, Yasuyuki Endo, Motonori Tsuji, Emiko Kawachi, Hiroyuki Kagechika, Koichi Shudo. Dicarba-closo-dodecaboranes as a Pharmacophore. Retinoidal Antagonists and Potential Agonists. Chem. Pharm. Bull., 1999, 47, 398-404.
Masayuki Ebisawa, Hiroki Umemiya, Kiminori Ohta, Hiroshi Fukasawa, Emiko Kawachi, Ghislaine Christoffel, Hinrich Gronemeyer, Motonori Tsuji, Yuichi Hashimoto, Koichi Shudo, Hiroyuki Kagechika. Retinoid X Receptor-Antagonistic Diazepinylbenzoic Acids. Chem. Pharm. Bull.,1999, 47, 1778-1786.
Wei Yang, Zaiqiang Yu, Mari Chiyoya, Xu Liu, Kazuyuki Daitoku, Shigeru Motomura, Tadaatsu Imaizumi, Ikuo Fukuda, Ken-Ichi Furukawa, Motonori Tsuji, Kazuhiko Seya. Menaquinone-4 Accelerates Calcification of Human Aortic Valve Interstitial Cells in High-Phosphate Medium through PXR. J. Pharmacol. Exp. Ther., 372, 277-284, 2020.
RƒEƒCƒ‹ƒX
Uranan Tumkosit, Uamporn Siripanyaphinyo, Naokazu Takeda, Motonori Tsuji, Yusuke Maeda, Kriangsak Ruchusatsawat, Tatsuo Shioda, Hiroto Mizushima, Prukswan Chetanachan, Pattara Wongjaroen, Yoshiharu Matsuura, Masashi Tatsumi, Atsushi Tanaka. Anti-chikungunya Virus Monoclonal Antibody Inhibiting Viral Fusion and Release. J Virol., 2020. DOI: 10.1128/JVI.00252-20.
Riho Tateyama-Makino, Mari Abe-Yutori, Taku Iwamoto, Kota Tsutsumi, Motonori Tsuji, Satoru Morishita, Kei Kurita, Yukio Yamamoto, Eiji Nishinaga, Keiichi Tsukinoki.The inhibitory effects of toothpaste and mouthwash ingredients on the interaction between the SARS-CoV-2 spike protein and ACE2, and the protease activity of TMPRSS2 in vitro. PLOS ONE, 16, e0257705-e0257705, 2021.
ƒTƒCƒgƒJƒCƒ“
Motonori Tsuji, Yukiko Koiso, Hiroyasu Takahashi, Yuichi Hashimoto, Yasuyuki Endo. Modulators of Tumor Necrosis Factor a Production Bearing Dicarba-closo-dodecaborane as a Hydrophobic Pharmacophore. Biol. Pharm. Bull., 2000, 23, 513-516.
A•¨ƒzƒ‹ƒ‚ƒ“
Motonori Tsuji, Eiichi Kuwano, Tetsuya Saito, Morifusa Eto. Root Growth-promoting Activities of N-Acyl-L-proline Derivatives. Biosci. Biotech. Biochem.,1992, 56, 778-782.
_Œo“`’B•¨Ž¿
Norio Ogata, Hideaki Tagishi, Motonori Tsuji. Inhibition of Acetylcholinesterase by Wood Creosote and Simple Phenolic Compounds. Chem. Pharm. Bull., 68, 1193-1200, 2020.
Ž©ŒÈ–ƉuŽ¾Š³
R¶•¨Ž¿
•ªŽqÝŒvi˜_—“Iƒhƒ‰ƒbƒOƒfƒUƒCƒ“jEƒCƒ“ƒVƒŠƒR‘n–ò
’҈꓿.* —L‹@‡¬‰»ŠwŽÒ‚Ì‚½‚߂̘_—“Iƒhƒ‰ƒbƒOƒfƒUƒCƒ“. •ªŽq‹@”\Œ¤‹†Š‹I—v, 2006, 1-9.
’҈꓿.* \‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€, HMHC‚¨‚æ‚ÑDSHC‚ÌŠJ”. Mol. Sci., 2007, 1, NP004.
Motonori Tsuji,* Koichi Shudo, Hiroyuki Kagechika. Docking Simulations Suggest that all-trans Retinoic Acid Could Bind to Retinoid X Receptors. J. Comput. Aided Mol. Des., 2015, 29, 975-988.iŠT—vj
Motonori Tsuji.* A Ligand-Entry Surface of the Nuclear Receptor Superfamily Consists of the Helix H3 of the Ligand-Binding Domain.J. Mol. Graph. Model., 2015, 62, 262-275.iŠT—vj
Motonori Tsuji,* Koichi Shudo, Hiroyuki Kagechika. Identifying the Receptor Subtype Selectivity of Retinoid X and Retinoic Acid Receptors via Quantum Mechanics. FEBS Open Bio., 2017, 7, 391-396, DOI: 10.1002/2211-5463.12188.iŠT—vj
Motonori Tsuji.* Antagonist-Perturbation Mechanism for Activation Function-2 Fixed Motifs: Active Conformation and Docking Mode of Retinoid X Receptor Antagonists. J. Comput. Aided Mol. Des., 2017, 31, 577-585, DOI: 10.1007/s10822-017-0025-6.iŠT—vj
\‘¢¶•¨Šw
Motonori Tsuji.* Local Motifs Involved in the Canonical Structure of the Ligand-Binding Domain in the Nuclear Receptor Superfamily. J. Struct. Biol., 2014, 185, 355-365.iŠT—vj
—˜_‰»Šw
Tomohiko Ohwada, Masanobu Uchiyama, Motonori Tsuji, Iwao Okamoto, Koichi Shudo. Orbital Unsymmetrization of Olefins Arising from Non-equivalent Orbital Interactions. s-p Coupling in Bicyclo[2.2.2]octenes. Chem. Pharm. Bull.,1996, 44, 296-306.
Tomohiko Ohwada, Motonori Tsuji, Iwao Okamoto, Koichi Shudo. A Remote Substituent Can Determine Magnitude of Facial Selectivity in Benzobicyclo[2.2.2]octatrienes. Tetrahedron Lett., 1996, 37, 2609-2612.
Motonori Tsuji, Tomohiko Ohwada, Koichi Shudo. A cyclopropyl Group Shows Reverse Facial Selectivity Depending on the Bicyclic Ring System. Tetrahedron Lett., 1997, 38, 6693-6696.
Motonori Tsuji, Tomohiko Ohwada, Koichi Shudo. Facial Selectivities of Benzofluorenes Bearing a Carbonyl, an Olefin, or a Diene Group in Spiro Geometry. p Spiro Substituent Effects. Tetrahedron Lett., 1998, 39, 403-406.
Motonori Tsuji.* On Attempts at Generation of Carboranyl Carbocation. J. Org. Chem., 2003, 68, 9589-9597.iŠT—vj
Motonori Tsuji.* Most Stable Conformation of the Cyclopropane Ring Attached at a Carbon Atom in a 1,2-Dicarba-closo-dodecaborane(12) System. J. Org. Chem., 2004, 69, 4063-4074.iŠT—vj
Motonori Tsuji.* Geometrical Dependence of the Highest Occupied Molecular Orbital in Bicyclic Systems: p Facial Stereoselectivity of Bicyclic and Tricyclic Olefins. Asian J. Org. Chem., 2015, 4, 659-673.iŠT—vj
–³‹@‰»Šw
Yasuyuki Endo, Kyoko Yaguchi, Motonori Tsuji, Kentaro Yamaguchi, Koichi Shudo. Functionalization of Polymethylcarboranes. Preparation and Reactivity of 2,3,4,5,6,7,8,9,10,11-Decamethyl-1,12-dicarba-closo-dodecaborane(12)-1-carboxylic Acid. Chem. Pharm. Bull., 1999, 47, 699-701.
ŠwˆÊ˜_•¶
’҈꓿.* uƒrƒVƒNƒ‚¨‚æ‚уXƒsƒƒIƒŒƒtƒBƒ“‚Ì”½‰ž–Ê‘I‘ð«‚ðŒˆ’è‚·‚é‹O“¹‘ŠŒÝì—pvA“Œ‹ž‘åŠwA–òŠw”ŽŽmA‘æ13735†A172•ÅA1998”N3ŒŽ11“úAŽå¸FŽñ“¡hˆê‹³ŽöAŽÄú±³Ÿ‹³ŽöA•ŸŽR“§‹³ŽöA’·–ì“N—Y‹³ŽöA¬“c“ˆ˜a“¿•‹³Žö.
Motonori Tsuji.* Synthesis and Plant Growth Regulation Activity of N-Acyl-L-proline DerivativesA‹ãB‘åŠwA”_ŠwCŽmA‘æ1964†A63•Åi‰¢•¶jA1992”N3ŒŽ27“úAŽå¸F]“¡Žç‘‹³ŽöA’JŒû‰h“ñ‹³ŽöAŒK–ì‰hˆê•‹³Žö.
Motonori Tsuji.* Synthesis and Biological Activity of Abscisic Acid MimicsA‹ãB‹¤—§‘åŠwAHŠwŽmA‘æ3398†A45•Åi‰¢•¶jA1990”N3ŒŽ20“úAŽå¸F‹g씎“¹‹³Žö.
Šw‰ï”•\
µ‘Òu‰‰EˆË—Šu‰‰
Z’҈꓿. µ‘Òu‰‰AAutoDock‚¨‚æ‚ÑAutoDock Vina‚ÌŠT—v‚ÆŽg—p•û–@FƒtƒŠ[ƒ\ƒtƒg‚¾‚¯‚ÅŽÀŽ{‚·‚é\‘¢ƒx[ƒXƒhƒ‰ƒbƒOƒfƒUƒCƒ“. –kŠC“¹‰ÈŠw‘åŠwA2023”N8ŒŽ10“úAŒvŽZ‰ÈŠw‹Zp‚𬒷“I”“W‚É“±‚ƒvƒƒtƒFƒbƒVƒ‡ƒiƒ‹lވ笂̑«ê‚‚èAƒIƒ“ƒ‰ƒCƒ“.
Z’҈꓿. \‘¢ƒx[ƒX‘n–òŠî”Õ‹Zp‚ÌŒ¤‹†ŠJ”‚Æ‚»‚̉ž—pFŠj“àŽó—e‘̃ŠƒKƒ“ƒhACOVID-19Ž¡—Öò‚̃hƒ‰ƒbƒOƒfƒUƒCƒ“. ˆê”ÊŽÐ’c–@lŠé‹ÆŒ¤‹†‰ïA2021”N5ŒŽ14“úA‘æ34ŠúCAMMƒtƒH[ƒ‰ƒ€AƒIƒ“ƒ‰ƒCƒ“.
›’҈꓿. ”½‰ž–Ê‘I‘ð«‚ðŽx”z‚·‚é‹O“¹‘ŠŒÝì—p—˜_AŠj“àƒŒƒZƒvƒ^[ƒŠƒKƒ“ƒhŒ‹‡—̈泀ƒtƒH[ƒ‹ƒh‚ÉŠÖ‚í‚é‹ÇŠƒ‚ƒ`[ƒt—˜_AŠj“àƒŒƒZƒvƒ^[ƒŠƒKƒ“ƒh”FŽ¯‚É‚¨‚¯‚éƒhƒ‰ƒCƒrƒ“ƒOƒtƒH[ƒXA‚»‚µ‚Ä\‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€‚ÌŠJ”. ˆê”ÊŽÐ’c–@lŠé‹ÆŒ¤‹†‰ïA2008”N1ŒŽ11“úA‘æ21ŠúCAMMƒtƒH[ƒ‰ƒ€A“Œ‹ž•\ŽQ“¹uƒAƒCƒr[ƒz[ƒ‹ÂŠw‰ïŠÙv.
‘ÛŠw‰ï
Riho Tateyama-Makino, Mari Abe-Yuroi, Taku Iwamoto, Kota Tsutsumi, Motonori Tsuji, Satoru Morishita, Kei Kurita, Eiji Nishinaga, Yukio Ymamamoto, Keiichi Tsukinoki. Inhibitory effects of toothpaste and mouthwash ingredients on SARS-CoV-2 infection in vitro. International Association for Dental Research, 2022”N6ŒŽ.
Kota Tsutsumi, Riho Tateyama-Makino, Mari Abe-Yuroi, Taku Iwamoto, Motonori Tsuji, Satoru Morishita, Kei Kurita, Eiji Nishinaga, Yukio Ymamamoto, Keiichi Tsukinoki. Inhibitory effects of toothpaste and mouthwash ingredients on SARS-CoV-2 infection in vitro. EuroPerio10, 2022”N6ŒŽ.
Taku Iwamoto, Riho Tateyama-Makino, Mari Abe-Yutori, Kota Tsutsumi, Motonori Tsuji, Satoru Morishita, Kei Kurita, Eiji Nishinaga, Yukio Yamamoto, Keiichi Tsukinoki. The inhibitory effects of toothpaste and mouthwash ingredients on SARS-CoV-2 spike protein-ACE2 interaction, and TMPRSS2 protease activity in vitro. The 14th International Conference of Asian Academy of Preventive DesityA2021”N10ŒŽ.
Uranan TumkositAMotonori TsujiAPattara WongjaoenAMasashi TatsumiAAtsushi Tanaka. Neutraliznig Mechanism of A Monoclonal Antibody Specific to Chikunguya Virus Thai #16856 StrainAAsian-African Research Forum on Emerging and Reemerging Infections 2019A2019”N9ŒŽ.
Ebisawa, MasayukiATashima, ToshihikoATsuji, MotonoriAFukasawa, HiroshiAKawachi, EmikoAHashimoto, YuichiAShudo, KoichiAKagechika, Hiroyuki. Novel Retinoids Having a Thiazolidinedione GroupA216th ACS National MeetingABostonA1998”N8ŒŽ.
Ohta, KiminoriATsuji, MotonoriAKawachi, EmikoAFukasawa, HiroshiA Hashimoto, YuichiAShudo, KoichiAKagechika, Hiroyuki. Novel Diphenylamine Derivatives with Potent Retinoid Synergistic ActivityA216th ACS National MeetingABostonA1998”N8ŒŽ.
ˆê”Êu‰‰“™
‰Yì—›‰ÔA—L“c‘ì–îA’҈꓿A´…NŒõ. ƒÀ-ƒOƒŠƒ`ƒ‹ƒŒƒ`ƒ“Ž_‚̃}ƒgƒŠƒbƒNƒXƒƒ^ƒƒvƒƒeƒA[ƒ[‘jŠQŒø‰Ê‚ɂ‚¢‚ÄA‘æ66‰ñt‹G“ú–{Ž•Žü•aŠw‰ïŠwp‘å‰ïA2023”N5ŒŽ.
Šâ–{‘ñA–q–ìä»”¿A—M’¹áÁ—¢A’çN‘¾A’҈꓿AX‰º‘AŒI“cŒ[AŽR–{KŽiAŽR–{K•vA’Ζ،bˆê. Ž•–ܬ•ª‚ÌVŒ^ƒRƒƒiƒEƒCƒ‹ƒX(SARS-CoV-2)Š´õŠÖ˜AˆöŽq‚ɑ΂·‚é‘jŠQì—pA‘æ1‰ñ“ú–{‘Á‰tƒPƒAŒ¤‹†‰ïŠwpW‰ïA2022”N11ŒŽ.
›’҈꓿. ƒCƒ“ƒVƒŠƒRƒXƒNƒŠ[ƒjƒ“ƒO‚ÆCADD‚É‚æ‚éCOVID-19Ž¡—ÖòŒó•â‰»‡•¨‚Ì’TõŒ¤‹†A‘æ50‰ñ\‘¢Šˆ«‘ŠŠÖƒVƒ“ƒ|ƒWƒEƒ€A2022”N11ŒŽ.
‰ª‘º‰À“ÞA’I’Jˆ»A’҈꓿A‘O“c—T•ãA‰e‹ßO”V. COVID-19Ž¡—ÖòŠJ”‚ð–Ú“I‚Æ‚µ‚½ERƒŠƒKƒ“ƒh‚Ì\‘¢“WŠJA•¶•”‰ÈŠwÈ‹¤“¯—˜—pE‹¤“¯Œ¤‹†‹’“_¶‘̈㎕HŠw‹¤“¯Œ¤‹†‹’“_—ߘa3”N“x¬‰Ê•ñ‰ïA2022”N3ŒŽ.
‰Ä–{•¶‹PA¯“cG•¶A‰iŸº‘×—YA‘å’Ã^A’҈꓿AŽR–{ˆê•FA’JŒû‰pŽ÷A“¡”ö‰ÀŽu. SLEŠ³ŽÒ—R—ˆiPS×–E‚ð—p‚¢‚½rare variants‚Ì’Tõ‚ƖƉuŠw“I‹@˜‚̉ð–¾A‘æ5‰ñ“ú–{–Ɖu•s‘SEŽ©ŒÈ‰ŠÇŠw‰ï‘‰ïA2022”N2ŒŽ.
—M’¹áÁ—¢A’çN‘¾A’҈꓿AŒI“cŒ[A¼‰i‰pŽiA’Ζ،bˆê. VŒ^ƒRƒƒiƒEƒCƒ‹ƒXiSARS-CoV-2jŠ´õŠÖ˜AˆöŽqSƒ^ƒ“ƒpƒN-ACE2Œ‹‡‚ɑ΂·‚鎕–Ü‹y‚ÑôŒûܬ•ª‚Ì‘jŠQì—p. ‘æ63‰ñŽ•‰ÈŠî‘bˆãŠw‰ïŠwp‘å‰ïA2021”N10ŒŽ.
–q–ìä»”¿AŠâ–{‘ñA’҈꓿AX‰º‘AŽR–{K•vA’Ζ،bˆê. VŒ^ƒRƒƒiƒEƒCƒ‹ƒXiSARS-CoV-2jŠ´õŠÖ˜AˆöŽqTMPRSS2Šˆ«‚ɑ΂·‚鎕–Ü‹y‚ÑôŒûܬ•ª‚Ì‘jŠQì—p. ‘æ63‰ñŽ•‰ÈŠî‘bˆãŠw‰ïŠwp‘å‰ïA2021”N10ŒŽ.
‰Á“¡—z“ñAÄ–{ç—¢AˆÉ“¡”ü‹IŽqA’҈꓿A’O‰H—˜•vA¼ì”ü‰FA¶é^ˆê. A•¨ƒtƒBƒgƒPƒ~ƒJƒ‹‹y‚Ñ‚»‚Ì‘ãŽÓ•¨‚É‚æ‚éƒRƒƒiƒEƒCƒ‹ƒX3CLƒvƒƒeƒA[ƒ[‘jŠQA“ú–{”_Œ|‰»Šw‰ï2021”N“x‘å‰ïA2021”N3ŒŽ.
Z’҈꓿A‰e‹ßO”V. \‘¢ƒx[ƒX‘n–ò‚ÉŠî‚ÂCOVID-19Ž¡—ÖòŒó•â‰»‡•¨‚Ì’TõŒ¤‹†A•¶•”‰ÈŠwÈ ‹¤“¯—˜—pE‹¤“¯Œ¤‹†‹’“_ ¶‘̈㎕HŠw‹¤“¯Œ¤‹†‹’“_ —ߘa2”N“x¬‰Ê•ñ‰ïA2021”N3ŒŽ.
Z’҈꓿A‰e‹ßO”V. COVID-19Ž¡—ÖòŒó•â‰»‡•¨‚Ì“¯’èFŠj“àŽó—e‘̃ŠƒKƒ“ƒhƒf[ƒ^ƒx[ƒX‚ð—p‚¢‚½SARS-CoV-2ƒƒCƒ“ƒvƒƒeƒA[ƒ[‚ɑ΂·‚éƒo[ƒ`ƒƒƒ‹ƒXƒNƒŠ[ƒjƒ“ƒOA‘æ31‰ñ“ú–{ƒŒƒ`ƒmƒCƒhŒ¤‹†‰ïŠwpW‰ïA2020”N10ŒŽ.
‰Á“¡—z“ñA¶é^ˆêA’҈꓿. A•¨¬•ª‹y‚Ñ‚»‚Ì‘ãŽÓŽY•¨‚É‚æ‚éƒRƒƒiƒEƒCƒ‹ƒX‚̃vƒƒeƒA[ƒ[‘jŠQA‘—§Œ¤‹†ŠJ”–@l‰ÈŠw‹ZpU‹»‹@\ƒCƒmƒx[ƒVƒ‡ƒ“ƒWƒƒƒpƒ“2020o“WA2020”N9ŒŽ`2020”N11ŒŽ.
›’҈꓿. ƒCƒ“ƒVƒŠƒR‘n–òƒVƒXƒeƒ€ADocking Study with HyperChemiDSHCj‚ÆHomology Modeling Professional for HyperChemiHMHCj‚É‚æ‚é‘n–òŠî”Õ‹Zp‚Ì‚“x‰»A“ú–{ƒRƒ“ƒsƒ…[ƒ^‰»Šw‰ïA2018”N6ŒŽ.
›’҈꓿. AF-2ŒÅ’胂ƒ`[ƒtÛ“®ƒƒJƒjƒYƒ€FƒŒƒ`ƒmƒCƒhXƒŒƒZƒvƒ^[ƒAƒ“ƒ^ƒSƒjƒXƒg‚ÌŠˆ«ƒRƒ“ƒtƒHƒ[ƒVƒ‡ƒ“‚ƃhƒbƒLƒ“ƒOƒ‚[ƒhA“ú–{–òŠw‰ï”N‰ïA2018”N3ŒŽ.
›’҈꓿AŽñ“¡hˆêA‰e‹ßO”V. ƒhƒbƒLƒ“ƒOAQM/MMA‘SŒn—ÊŽq—ÍŠwŒvŽZ‚É‚æ‚郌ƒ`ƒmƒCƒh‚̃ŒƒZƒvƒ^[ƒTƒuƒ^ƒCƒv‘I‘𫎯•ÊFATRA‚Í“àˆö«RXRƒŠƒKƒ“ƒh‚Æ‚µ‚Äì—p‚·‚éA‘æ28‰ñ“ú–{ƒŒƒ`ƒmƒCƒhŒ¤‹†‰ïŠwpW‰ïA2017”N11ŒŽ.
›’҈꓿. ƒwƒŠƒbƒNƒX3ŽO“_‰ŠúŒ‹‡‰¼àFŠj“àŽó—e‘̃X[ƒp[ƒtƒ@ƒ~ƒŠ[‚̃ŠƒKƒ“ƒhŒ‹‡—̈æ‚É‚¨‚¯‚郊ƒKƒ“ƒh•â‘«ƒƒJƒjƒYƒ€‚ƃAƒ|‘Ì‚©‚çƒzƒ‘Ì‚Ö‚Ì\‘¢‘JˆÚ‚ÉŠÖ‚·‚é—‰ðA“ú–{–òŠw‰ï”N‰ïA2017”N3ŒŽ.
›’҈꓿. ƒrƒVƒNƒŒn‚É‚¨‚¯‚éÅ‚”í蕪Žq‹O“¹‚ÌŠô‰½Šw“IˆË‘¶FƒrƒVƒNƒƒIƒŒƒtƒBƒ“‚Ì”½‰ž–Ê‘I‘ð«‚Ì‹NŒ¹A“ú–{–òŠw‰ï”N‰ïA2016”N3ŒŽ.
›’҈꓿. Šj“àŽó—e‘̃ŠƒKƒ“ƒhŒ‹‡—̈泀\‘¢‚ÉŠÖ‚í‚é‹ÇŠƒ‚ƒ`[ƒt\‘¢‚Æ‚»‚Ì‹@”\A“ú–{–òŠw‰ï”N‰ïA2015”N3ŒŽ.
‘¾“cŒö‹KA’҈꓿A‰Í“àŒb”üŽqA[àVOŽuA‰e‹ßO”V;@“Œ‘啪¶Œ¤@‹´–{—Sˆê. Šj“àƒŒƒ`ƒmƒCƒhŽó—e‘Ì‚Éì—p‚·‚éƒsƒŠƒ~ƒWƒ“ƒJƒ‹ƒ{ƒ“Ž_A“ú–{–òŠw‰ï”N‰ïA2000”N3ŒŽ.
‘¾“cŒö‹KA’҈꓿A‰Í“àŒb”üŽqA[àVOŽuA‰e‹ßO”VAŽñ“¡hˆê;@“Œ‘啪¶Œ¤@‹´–{—Sˆê. V‹KƒŒƒ`ƒmƒCƒh§Œä‰»‡•¨‚Ì‘n»A“ú–{–òŠw‰ï”N‰ïA1998”N3ŒŽ.
›’҈꓿A‘å˜a“c’q•FAŽñ“¡hˆê. Diels-AlderƒWƒGƒ“‚̃ΖʑI‘ð«A“ú–{–òŠw‰ï”N‰ïA1997”N3ŒŽ.
›’҈꓿A‘å˜a“c’q•FA“àŽR^LAŽñ“¡hˆêG@ç—t‘啪Í@ŽRŒûŒ’‘¾˜Y. ƒrƒVƒNƒ[2.2.2]ƒIƒNƒeƒ“‚É‚¨‚¯‚éƒÎ–Ê‘I‘ð«‚ւ̃VƒNƒƒvƒƒpƒ“ŠÂ‚ÌŒø‰ÊA“ú–{–òŠw‰ï”N‰ïA1996”N3ŒŽ.
›’҈꓿A‘å˜a“c’q•FAŽñ“¡hˆê. ƒÎ\ƒÎ‹O“¹‘ŠŒÝì—p‚É‚æ‚éƒÎ–Ê”ñ“™‰¿‚Ì—§‘Ì‘I‘ð«‚É‹y‚Ú‚·‰e‹¿A“ú–{–òŠw‰ï”N‰ïA1995”N3ŒŽ.
“‡è‰p•vA’҈꓿A‰e‹ßO”VA‰Í“àŒb”üŽqAŽñ“¡hˆê. ƒAƒ~ƒh‚Ì—§‘̉»Šw‚ðŠˆ—p‚µ‚½V‹KƒŒƒ`ƒmƒCƒh‚̇¬‚ÆŠˆ«A“ú–{–òŠw‰ï”N‰ïA1994”N3ŒŽ.
›’҈꓿A‘å˜a“c’q•FAŽñ“¡hˆê. ƒAƒƒ}ƒeƒBƒbƒNƒXƒsƒƒPƒgƒ“‹y‚уIƒŒƒtƒBƒ“‚É‚¨‚¯‚éƒÎ–Ê‘I‘ð«A“ú–{–òŠw‰ï”N‰ïA1994”N3ŒŽ.
›’҈꓿AŒK–ì‰hˆêAÖ“¡“NÆA]“¡Žç‘. N-ƒAƒVƒ‹-L-ƒvƒƒŠƒ“—U“±‘Ì‚Ì—cªL’·‘£iŠˆ«A“ú–{”_Œ|‰»Šw‰ï”N‰ïA1991”N3ŒŽ.
›’҈꓿AŒK–ì‰hˆêA]“¡Žç‘. ƒvƒƒŠƒ“—U“±‘Ì‚ÌA•¨¶ˆç‚É‹y‚Ú‚·‰e‹¿AA•¨‰»Šw’²ßŠw‰ï”N‰ïA1991”N3ŒŽ.
ƒ[ƒNƒVƒ‡ƒbƒv
’҈꓿. i‹¤“¯jA\‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€iVirtual Screening SystemADocking Study with HyperChemAHomology Modeling for HyperChemAONIOM Interface for ReceptorAGaussian Interface for HyperChemjA‘æ8‰ñ“ú–{’`”’Ž¿‰ÈŠw‰ï”N‰ïA2008”N6ŒŽ.
’҈꓿.i‹¤“¯jA\‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€iVirtual Screening SystemADocking Study with HyperChemAHomology Modeling for HyperChemAONIOM Interface for ReceptorAGaussian Interface for HyperChemjA“ú–{–òŠw‰ï‘æ128”N‰ïA2008”N3ŒŽ.
’҈꓿.i‹¤“¯jA\‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€iVirtual Screening SystemADocking Study with HyperChemAHomology Modeling for HyperChemAONIOM Interface for ReceptorAGaussian Interface for HyperChemjA‘æ45‰ñ“ú–{¶•¨•¨—Šw‰ïA2007”N12ŒŽ.
’҈꓿.i‹¤“¯jA\‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€iVirtual Screening SystemADocking Study with HyperChemAHomology Modeling for HyperChemAONIOM Interface for ReceptorAGaussian Interface for HyperChemjA‘æ30‰ñ“ú–{•ªŽq¶•¨Šw”N‰ïE‘æ80‰ñ“ú–{¶‰»Šw‰ï‘å‰ï‡“¯‘å‰ïA2007”N12ŒŽ.
’҈꓿.i‹¤“¯jA\‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€iVirtual Screening SystemADocking Study with HyperChemAHomology Modeling for HyperChemAONIOM Interface for ReceptorAGaussian Interface for HyperChemjA“ú–{–òŠw‰ï‘æ127”N‰ïA2007”N3ŒŽ.
’҈꓿.i‹¤“¯jA\‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€iVirtual Screening SystemADocking Study with HyperChemAHomology Modeling for HyperChemAONIOM Interface for ReceptorAGaussian Interface for HyperChemjA“ú–{•ªŽq¶•¨Šw‰ï2006ƒtƒH[ƒ‰ƒ€A2006”N12ŒŽ.
’҈꓿.i‹¤“¯jA\‘¢ƒx[ƒX‘n–òŽx‰‡ƒVƒXƒeƒ€iVirtual Screening SystemADocking Study with HyperChemAHomology Modeling for HyperChemAONIOM Interface for ReceptorAGaussian Interface for HyperChemjA“ú–{ƒRƒ“ƒsƒ…[ƒ^‰»Šw‰ïA2006”N6ŒŽ.
•ªŽq‹@”\Œ¤‹†Š‚ª‘åã‘åŠwA‹ž“s•{—§ˆã‰È‘åŠw‚Æ‚ª‚ñŽ¡—Öò‚ÌŠJ”‚ð–ÚŽw‚µ‚½‹¤“¯Œ¤‹†‚ðŠJŽnA2023”N11ŒŽ1“ú.
•ªŽq‹@”\Œ¤‹†Š‚ªƒCƒ“ƒVƒŠƒRƒXƒNƒŠ[ƒjƒ“ƒO‚Å—LŒø¬•ª‚𔌩F–¯ŠÔŒ¤‹†‹@ŠÖ‚©‚烃Cƒ„ƒŠƒeƒB‚ðŽó—ÌA2023”N10ŒŽ23“ú.
VŒ^ƒRƒƒiƒEƒCƒ‹ƒXiCOVID-19jŽ¡—ÖòŒó•â‰»‡•¨ƒŠƒXƒg‚ð”•\F¢ŠEÅ‚…€‚̃Rƒ“ƒsƒ…[ƒ^ƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚É‚æ‚éˆã–ò•i•ªŽqÝŒv•û–@˜_‚Ŭ‰ÊA2022”N9ŒŽ21“ú.
ƒnƒ~ƒKƒL‚È‚Ç‚ÉŽg‚í‚ê‚鬕ª‚ªŒûo“à‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚ÌŽå—vŠ´õŒo˜H‚ð‘jŠQA2021”N10ŒŽ4“ú.
RVŒ^ƒRƒƒiƒEƒCƒ‹ƒXiSARS-CoV-2j–ò‚̈ã–ò•iŒó•âƒŠƒXƒg‚ð”•\A2020”N5ŒŽ9“ú.
—ÊŽq—ÍŠwŒvŽZ‚É‚æ‚èˆã–ò•i‚ÌŽó—e‘̃Tƒuƒ^ƒCƒv‘I‘ð«‚Ì—\‘ªEÄŒ»‚ɬŒ÷A2017”N2ŒŽ15“ú.
Šj“àŽó—e‘̃X[ƒp[ƒtƒ@ƒ~ƒŠ[‚É‚¨‚¯‚郊ƒKƒ“ƒh”FŽ¯‹@\‚ÌŒ´—‚̉𖾂ɬŒ÷A2015”N11ŒŽ4“ú.
—L‹@‰»Šw”½‰ž‚É‚¨‚¯‚éd—v–¢‰ðŒˆ–â‘è‚Å‚ ‚锽‰ž–Ê—§‘Ì‘I‘ð«‚Ì–{Ž¿“IŒ´—‚̉𖾂ɬŒ÷A2015”N4ŒŽ17“ú.
ƒAƒ~ƒmŽ_”z—ñiˆêŽŸ\‘¢j‚©‚çƒ^ƒ“ƒpƒNŽ¿‚Ì—§‘Ì\‘¢iŽOŽŸ\‘¢j‚ªŒ`¬‚³‚ê‚郃JƒjƒYƒ€‚̈ê’[‚ðŒ´ŽqE“dŽqƒŒƒxƒ‹‚ʼn𖾂·‚邱‚ƂɬŒ÷Aˆã–ò•i‚â”_–ò‚ªŒø‰Ê‚ðŽ¦‚·ƒƒJƒjƒYƒ€‚̈ê’[‚𖾂炩‚É‚µ‚½A2013”N12ŒŽ23“ú.
•ªŽq‹@”\Œ¤‹†ŠiInstitute of Molecular Functionj‚ªƒRƒ“ƒsƒ…[ƒ^ã‚ňã–òŒó•â‰»‡•¨‚ðƒXƒNƒŠ[ƒjƒ“ƒO‚Å‚«‚éƒVƒXƒeƒ€‚ð‘ŽY‚Æ‚µ‚Ă͉‚ß‚Ä‘“àŠO‚̈ê”ÊŽsê‚Ŕ̔„ŠJŽn‚·‚éA2006”N11ŒŽ16“ú.
•ªŽq‹@”\Œ¤‹†ŠiInstitute of Molecular Functionj‚ªAŽ¾Š³‚ÉŠÖ‚í‚éƒ^ƒ“ƒpƒNŽ¿‚Ì—§‘Ì\‘¢‚Ì‚Ý‚©‚çA‚»‚ÌŽ¾Š³‚ɑ΂·‚éˆã–òŒó•â‰»‡•¨‚ð‚¸“x‚É—\‘ª‚Å‚«‚颊E‰‚ÌŠvV‹Zp‚ðŠJ”A2006”N5ŒŽ8“ú.
Institute of Molecular Function‚ªuHyperChemv‚©‚çuGaussianv‚ðŽÀs‚·‚邽‚߂̃Cƒ“ƒ^[ƒtƒFƒCƒXuGaussian Interface for HyperChemv‚ðŠJ”A‚±‚ê‚É‚æ‚袊EÅ‹ŒvŽZ‰»ŠwŠÂ‹«‚ðŽÀŒ»A2005”N8ŒŽ22“ú.
Institute of Molecular Function‚ª‚«”\ƒ^ƒ“ƒpƒNƒ‚ƒfƒŠƒ“ƒOŽx‰‡ƒVƒXƒeƒ€uHomology Modeling for HyperChemv‚ðŠJ”A2005”N7ŒŽ11“ú.
‹LŽ–iŽæÞ‚ðŽó‚¯‚½‚à‚Ìj
u•ªŽq‹@”\Œ¤‹†Š‚ª‘åŠw‚Æ‚Ì‹¤“¯Œ¤‹†‚ð„iF‚ª‚ñŽ¡—Öò‚È‚ÇAŽó‘õŽ–‹Æ‚Ö‚à’e‚Ýv. CCSnewsA2023”N11ŒŽ7“ú.
u‘n–òŽó‘õŒ¤‹†‚ªD’²„ˆÚF‘n—§‚Q‚OŽü”N‚ŃLƒƒƒ“ƒy[ƒ“‚àv. ‰»ŠwH‹Æ“ú•ñA2023”N6ŒŽ29“úA7–Ê.
uˆã—ÃŒnŽó‘õŒ¤‹†‚̈˗Š‘FƒRƒƒiŠÖ˜A‚âhRÜÝŒv‚È‚Çv. ‰»ŠwH‹Æ“ú•ñA2022”N6ŒŽ29“úA7–Ê.
uƒRƒƒiŽ¡—Öò’Tõ‚Å’–ÚFSBDD‹ZpƒRƒA‚ÉŽó‘õŒ¤‹†v. ‰»ŠwH‹Æ“ú•ñA2021”N6ŒŽ30“úA7–Ê.
uVŒ^ƒRƒƒi‚ÌŒ¤‹†‚Ŭ‰ÊF‘å‹K–͉¼‘zƒXƒNƒŠ[ƒjƒ“ƒOv. ‰»ŠwH‹Æ“ú•ñA2020”N7ŒŽ16“úA7–Ê.
u“ÆŽ©‹Zp‚Å‘n–òŒ¤‹†Žx‰‡F‚“x‚ÈŒvŽZ‰»Šw‹@”\‚ð“‹Úv. ‰»ŠwH‹Æ“ú•ñA2019”N6ŒŽ17“úA9–Ê.
uƒhƒbƒLƒ“ƒO‰ðÍ‹@”\‚ðŠg[FŠO•”ƒ\ƒtƒg‚Ƃ̘AŒg‹‰»v. ‰»ŠwH‹Æ“ú•ñA2018”N6ŒŽ21“úA9–Ê.
uONIOM–@‚Æ“ÆŽ©‚ɘAŒgF•¡‡‘Ì\‘¢‚𸖧‰ðÍv. ‰»ŠwH‹Æ“ú•ñA2017”N6ŒŽ21“úA9–Ê.
u•ªŽq‹@”\Œ¤‹†ŠFONIOM‘Ήž‚ð‹‰»A‚½‚ñ‚Ï‚‚Ì‘SŒnŒvŽZ‚ɑΉžv. ‰»ŠwH‹Æ“ú•ñA2016”N6ŒŽ24“úA9–Ê.
u•ªŽq‹@”\Œ¤‹†ŠFƒXƒNƒŠ[ƒjƒ“ƒO‹@”\‚‘¬‰»A“ÆŽ©Žè–@‚Ì‘n–òƒ\ƒtƒgv. ‰»ŠwH‹Æ“ú•ñA2015”N6ŒŽ25“úA9–Ê.
u•ªŽq‹@”\Œ¤‹†ŠF“ÆŽ©‹Zp‚Å‘n–òŽx‰‡ƒ\ƒtƒgAƒhƒbƒLƒ“ƒO‰ðÍ‚ÅVŽè–@v. ‰»ŠwH‹Æ“ú•ñA2008”N6ŒŽ26“úA6–Ê.
u•ªŽq‹@”\Œ¤‹†ŠF‚“x‹@”\‚ðŽg‚¢‚â‚·‚’ñ‹ŸA“ÆŽ©ƒmƒEƒnƒE‚ÌSBDDv. ‰»ŠwH‹Æ“ú•ñA2007”N6ŒŽ29“úA6–Ê.
uŽŸ¢‘ã\‘¢ƒx[ƒX‚Ì‘n–òŽx‰‡ƒVƒXƒeƒ€‚ðŠJ”E”Ì”„‚·‚év. ‘ÛƒOƒ‰ƒtA 2007”N2ŒŽA290†A53•Å.
u–ò•¨E‚½‚ñ”’Ž¿ƒhƒbƒLƒ“ƒO‰ðÍFƒ}ƒ‹ƒ`‰»‡•¨”Å‚ð“Š“üA•ªŽq‹@”\Œ¤‚ªVƒc[ƒ‹A1–œŒÂ‚Ü‚ÅŽ©“®‰»v. ‰»ŠwH‹Æ“ú•ñA2006”N11ŒŽ24“úA9–Ê.
u•ªŽq‹@”\Œ¤‹†ŠF˜_—«dŽ‹‚Ì‘n–òŽx‰‡A“ú•Ä‰¢‚ł̔̔„‘̧‚àŠm—§v. ‰»ŠwH‹Æ“ú•ñA2006”N6ŒŽ29“úA6–Ê.
u•ªŽq‹@”\Œ¤‹†ŠFŽó—e‘Ì‘ŠŒÝì—p•”ˆÊ‚ðŽ©“®’TõFSBDD“‡ƒVƒXƒeƒ€ŠJ”A•W“I‚½‚ñ”’Ž¿‚ƈã–ò•ªŽqA˜_—“IƒhƒbƒLƒ“ƒO‰ðÍv. ‰»ŠwH‹Æ“ú•ñA2006”N5ŒŽ30“úA9–Ê.
u•ªŽq‹@”\Œ¤‹†ŠF‚½‚ñ”’Ž¿—ÊŽq‰»ŠwŒvŽZONIOM–@AŠ®‘SGUI‰»‚ðŽÀŒ»v. ‰»ŠwH‹Æ“ú•ñA2006”N1ŒŽ5“úA8–Ê.
uŒ¤‹†ŠJ”‚ÉV‚½‚È•û–@˜_ŠJ‚CCSv. ‰»ŠwH‹Æ“ú•ñA2005”N12ŒŽ8“úA5–Ê.
u•ªŽq‹@”\Œ¤F‘n–òŽx‰‡ƒ\ƒtƒg‚ð“ÆŽ©ŠJ”AÄŒ»«‚‚¢˜_—“Iƒ‚ƒfƒŠƒ“ƒO‚ª‰Â”\v. ‰»ŠwH‹Æ“ú•ñA2005”N10ŒŽ31“úA9–Ê.